On February 2, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported that it will present an abstract relating to the mechanism of action of rigosertib in combination with azacitidine at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on "Targeting DNA Methylation and Chromatin for Cancer Therapy". The conference is being held in Atlanta, Georgia, on March 1-4, 2018 at the Sheraton Atlanta Hotel.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentation are listed below.

Title: Rigosertib (RIG) Alone or in Combination with Azacitidine or Vorinostat has Chromatin Modifying Effects and Epigenetically Reprograms Hematopoietic Stem and Progenitor Cells in the Myelodysplastic Syndrome

Date: Friday, March 2, 2018

Presenter: Dr. Lewis Silverman, Mount Sinai School of Medicine